Search

Your search keyword '"Lanoy E"' showing total 304 results

Search Constraints

Start Over You searched for: Author "Lanoy E" Remove constraint Author: "Lanoy E"
304 results on '"Lanoy E"'

Search Results

10. Cémiplimab versus traitements systémiques historiques du carcinome épidermoïde cutané localement avancé ou métastatique : résultats de l’étude TOSCA

11. 1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA

16. 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis

20. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

21. PO-1227: A dose escalation phase 1 study of radiotherapy combined with ipilimumab in metastatic melanoma.

30. Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4‐FHDH)

31. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

32. Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

33. Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

38. Tolérance et efficacité des anticorps anti immune check-point inhibiteurs (anti PD-1/PD-L1) chez les patients atteints d’une maladie auto-immune ou inflammatoire

41. Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation

45. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

46. 1368P - Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

48. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

49. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

50. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

Catalog

Books, media, physical & digital resources